DGAP-Adhoc: aap Implantate AG resolves on capital increase with subscription rights to finance sales growth and start of human clinical study for antibacterial silver coating technology
DGAP-Ad-hoc: aap Implantate AG / Key word(s): Capital Increase/Financing
aap Implantate AG resolves on capital increase with subscription rights to finance sales growth and start of human clinical study for antibacterial silver coating technology
27-Sep-2021 / 08:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The Management Board of aap Implantate AG ("aap" or the "Company") resolved on 27 September 2021 with the approval of the Supervisory Board of the same day on a capital increase against cash contributions out of the authorized capital 2019/I with subscription and oversubscription rights of the shareholders of the Company. aap's share capital shall be increased by up to EUR 1,500,000.00 by issuing up to 1,500,000 new no-par value bearer shares from the current amount of EUR 3,478,243.00 to up to EUR 4,978,243.00. The new shares shall be offered to the shareholders of the Company at a subscription price of EUR 3.30 per new share based on a subscription ratio of 2.3189:1. The new shares are entitled to participate in dividends as of 1 January 2021.
At the present time, aap has commitments from its shareholders to exercise subscription and oversubscription rights and commitments from new investors to subscribe for new shares in the private placement with a total volume of approx. EUR 2.7 million. This corresponds to approx. 54% of the capital increase.
The issue proceeds from the transaction shall be used to finance the planned sales growth with a focus on the USA (especially investments in sets) and the start of the human clinical study for the Company's antibacterial silver coating technology in the fourth quarter of 2021.
The new shares will be offered to the shareholders of aap for subscription by way of an indirect subscription right during a subscription period. The subscription period is expected to start on 4 October 2021 (00.00 hours CEST) and to end on 18 October 2021 (24.00 hours CEST). No trading of subscription rights will be organized and subscription rights which are not exercised will expire worthless. In addition to exercising their subscription rights, all shareholders of the Company have the option to participate in the capital increase within an oversubscription. These oversubscription rights must also be exercised during the subscription period. New shares, which are not subscribed as part of the subscription offer, shall be offered to investors for sale by means of a private placement at a price at least equaling the subscription price per new share.
The capital increase with subscription rights is accompanied by BankM AG. For further details regarding the transaction please refer to the subscription offer, which will be published before the start of the subscription period on the corporate website of the Company (https://www.aap.de/) in the section "Investors / Capital Increase" as well as in the Federal Gazette under https://www.bundesanzeiger.de/.
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -
About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: [email protected]
27-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
||aap Implantate AG
||+49 (0) 30 75 01 90
||+49 (0) 30 75 01 91 11
||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
|EQS News ID:
|End of Announcement
||DGAP News Service
1235911 27-Sep-2021 CET/CEST
Quelle: boersengefluester.de und Firmenangaben
Die wichtigsten Finanzdaten auf einen Blick
|Ergebnis je Aktie8
Geschäftsbericht 2021 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
||Kurs in €
||Börsenwert in Mio. €
|Dividende '22 in €
||Dividende '23e in €
||Performance 52 Wochen